GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum3396310.26442/20795696.2020.1.200045REVIEWОБЗОРResearch ArticlePossibilities and prospects of conservative therapy for endometriosis, as a chronical progressing disease (review of literature)Возможности и перспективы консервативной терапии эндометриоза как хронического прогрессирующего заболевания (обзор литературы)https://orcid.org/0000-0003-0219-3400PestrikovaTatyana Yu.ПестриковаТатьяна Юрьевна
Russian Federation

D. Sci. (Med.), Prof.

д-р мед. наук, проф., зав. каф. акушерства и гинекологии

typ50@rambler.ruhttps://orcid.org/0000-0002-7771-3549YurasovaElena A.ЮрасоваЕлена Анатольевна
Russian Federation

D. Sci. (Med.), Prof.

д-р мед. наук, проф. каф. акушерства и гинекологии

urasovaea@yandex.ruhttps://orcid.org/0000-0001-6397-7052YurasovIgor V.ЮрасовИгорь Владимирович
Russian Federation

D. Sci. (Med.), Prof.

д-р мед. наук, проф. каф. акушерства и гинекологии

ivaiva@yandex.ruFar Eastern State Medical UniversityФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава России0105202022114183004202030042020Copyright ©; 2020, Consilium MedicumCopyright ©; 2020, ООО "Консилиум Медикум"2020Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/33963

Relevance. Endometriosis is a common gynecological disease that affects up to 10% of women of reproductive age worldwide and is the main cause of pain and infertility. Endometriosis is a disease, although it has been known for a long time, nevertheless, in many ways it represents terra incognita for modern medicine.

Aim. Analysis of literature on the feasibility of long-term and the use of the drug dienogest 2 mg (Vizanne), which has a positive effect on the quality of life of patients with endometriosis.

Materials and methods. To write this review, a search was made for domestic and foreign publications in Russian and international search engines (PubMed, eLibrary, etc.) over the past 13 years. The review included articles from peer-reviewed literature.

Results. The review presents data on the difficulties of verifying the diagnosis of endometriosis due to a combination of this pathology with pain, infertility, abnormal uterine bleeding. The pathogenesis of the origin of endometriosis-associated pain is presented. The efficacy of the use of the drug dienogest (Vizanne), which has a powerful antiproliferative effect that reduces the main symptoms of endometriosis (pain, bleeding), is substantiated. The expediency of long-term and safe use of the drug dienogest (Vizanne), which has a positive effect on the quality of life of patients with endometriosis, has been proved.

Conclusions. Numerous scientific publications confirm the feasibility of prolonged use of the drug dienogest (Vizanne), to achieve remission during endometriosis.

Актуальность. Эндометриоз – распространенное гинекологическое заболевание, которое поражает до 10% женщин репродуктивного возраста во всем мире и является главной причиной боли и бесплодия. Эндометриоз – заболевание, хотя и известное достаточно давно, тем не менее во многом представляющее terra incognita для современной медицины.

Цель. Проведение анализа литературных источников по целесообразности долгосрочного использования препарата диеногест 2 мг (Визанна), который продемонстрировал положительное влияние на качество жизни пациенток с эндометриозом.

Материалы и методы. Для написания данного обзора был осуществлен поиск отечественных и зарубежных публикаций в российских и международных системах поиска (PubMed, eLibrary и пр.) за последние 13 лет. В обзор были включены статьи из рецензируемой литературы.

Результаты. В обзоре представлены данные о трудностях верификации диагноза эндометриоза, обусловленных сочетанием данной патологии с болевым синдромом, бесплодием, аномальными маточными кровотечениями. Представлен патогенез происхождения эндометриозассоциированной боли. Продемонстрирован благоприятный профиль эффективности использования препарата диеногест 2 мг (Визанна), обладающего мощным антипролиферативным эффектом, снижающим главные симптомы при эндометриозе (боль, кровотечения). Показана целесообразность долгосрочного использования препарата диеногест 2 мг (Визанна), оказывающего положительное влияние на качество жизни пациенток с эндометриозом.

Выводы. Многочисленные научные публикации подтверждают целесообразность длительного использования препарата диеногест 2 мг (Визанна) для достижения ремиссии в течении эндометриоза.

endometriosisadenomyosispaininfertilityabnormal uterine bleedingdienogest drug 2 mg (Vizanne)эндометриозаденомиозболевой синдромбесплодиеаномальные маточные кровотеченияпрепарат диеногест 2 мг (Визанна)This article was prepared with the financial support from Bayer.Статья подготовлена при финансовой поддержке компании «Байер».Гинекология: национальное руководство. Под ред. Г.М.Савельевой, Г.Т.Сухих, В.Н.Серова и др. 2-е изд., перераб и доп. М.: ГЭОТАР-Медиа, 2017. [Gynecology: national leadership. Ed. G.M.Savelieva, G.T.Suhikh, V.N.Serov et al. 2nd ed., revised and ext. Moscow: GEOTAR-Media, 2017 (in Russian).]Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. Под ред. В.Н.Серова, Г.Т.Сухих, В.Н.Прилепской, В.Е.Радзинского. 3-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2016. [Guidelines for outpatient care in obstetrics and gynecology. Ed. V.N.Serov, G.T.Sukhikh, V.N.Prilepskaya, V.E.Radzinsky. 3rd ed., revised and ext. Moscow: GEOTAR-Media, 2016 (in Russian).]Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reproductive BioMedicine Online 2017. DOI: 10.1016/j.rbmo.2017.06.016Chapron C, Tosti C, Marcellin L et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 2017; 32 (7): 1393–401.Vercellini P, Abbiati A, Daguati R et al. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol 2008; 22 (2): 275–306.Kennedy S. Should a diagnosis of endometriosis be sought in all symptomatic women? Fertil Steril 2006; 86 (5): 1312–3.Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril 2017; 107: 555.Taylor HS, Giudice LC, Lessey BA et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017; 377: 28.Эндометриоз: диагностика, лечение и реабилитация. Федеральные клинические рекомендации по ведению больных. Коллектив авторов под руководством Л.В.Адамян. М., 2013. [Endometriosis: diagnosis, treatment and rehabilitation. Federal clinical guidelines for patient management. The team of authors led by L.V.Adamyan. Moscow, 2013 (in Russian).]Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol 2017; 209: 8–13.Mettler L, Alkatout I, Keckstein J et al. Endometriosis: a concise practical guide to current diagnosis and treatment. 2018.Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014; 348: g1752.Пестрикова Т.Ю., Пивкина О.А. Альтернативная схема лечения генитального эндометриоза. Дальневосточный мед. журн. 2007; 4: 95–7. [Pestrikova T.Iu., Pivkina O.A. Al’ternativnaia skhema lecheniia genital’nogo endometrioza. Dal’nevostochnyi med. zhurn. 2007; 4: 95–7 (in Russian).]Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2018; 5: CD001019. DOI: 10.1002/14651858.CD001019.pub3 [Epub ahead of print]Dunselman GAJ, Vermeulen N, Becker C et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29 (3): 400–12.Seracchioli R, Mabrouk M, Manuzzi L et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom recurrence after conservative surgery for endometriosis. Hum Reprod 2009; 24 (11): 2729–352.Harada T, Momoeda M, Taketani Y et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90 (5): 1583–8.Jenkins TR, Jenkins TR, Liu CY, White J. Does response to hormonal therapy predict presence or absence of endometriosis? J Minim Invasive Gynecol 2008; 15 (1): 82–6.Vercellini P, Eskenazi B, Consommi D et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update 2011; 17: 159–70.Chapron Ch, Souza C, Borghese B et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod 2011; 26 (8): 2028–35.Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril 2017; 107: 533–6.Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012: CD002122.Vercellini P, Bracco B, Mosconi P et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105: 734–43.Tosti C, Troìa L, Vannuccini S et al. Current and future medical treatment of adenomyosis. J Endometr Pelvic Pain Disord 2016; 8 (4): 127–35.Fedele L, Bianchi S, Frontino G. Hormonal treatments for adenomyosis. Best Pract Res Clin Obstet Gynaecol 2008; 22: 333–9.Hirata T, Izumi G, Takamura M et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol 2014; 30: 726–9.Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet 2015; 292 (6): 1267–71.Sugimoto K, Nagata C, Hayashi H et al. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res 2015; 41 (12): 1921–6.Osuga Y, Fujimoto-Okabe H, Haginob A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108: 673–8.Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis J Obstet Gynaecol Res 2017; 43 (9): 1441–8.Irahara M, Harada T, Momoeda M, Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 2007; 6: 223–8.Kissler S, Zangos S, Kohl J et al. Duration of dysmenorrhoea and extent of adenomyosis visualised by magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 2008; 137 (2): 204–9.Larsen SB, Lundorf E, Forman A, Dueholm M. Adenomyosis and junctional zone changes in patients with endometriosis. Eur J Obstet Gynecol Reprod Biol 2011;157 (2): 206–11.Petraglia F, Hornung D, Seitz C et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2011; 285 (1): 167–73.Momoeda М, Harada T, Terakawa N et al. Long-term use of dienogest for the treatment of endometriosis J Obstet Gynaecol Res 2009; 35 (6): 1069–76.Kohler G, Faustmann TA, Gerlinger C et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynecol Obstet 2010; 108: 21–5.Инструкция по применению Визанны. https://promatka.ru/endometrioz/vizanna-pri-endometrioze.html [Instruktsiia po primeneniiu Vizanny. https://promatka.ru/endometrioz/vizanna-pri-endometrioze.html (in Russian).]Инструкция по применению Визанны. https://yandex.ru/ health/pills/product/vizanna30174?utm_source=yandex&utm_medium=search&utm_campaign=yandex-searchster&utm_content=wizard-drugs&saas_webreqid=1579148090412612-218368876646320162303076-man1-3539 [Instruktsiia po primeneniiu Vizanny. https://yandex.ru/health/pills/product/vizanna30174?utm_source=yandex&utm_medium=search&utm_campaign=yandex-searchster&utm_content=wizard-drugs&saas_webreqid=1579148090412612-218368876646320162303076-man1-3539 (in Russian).]Аденомиоз: фокус на терапию. Гинекология. 2019; 21 (5): 16–9. DOI: 10.26-442/207956962019.5.190749 [Adenomyosis: focus on therapy. Gynecology. 2019; 21 (5): 16–9. DOI: 10.26442/20795696.2019.5.190749 (in Russian).]